The amplitude and origin of sea-level variability during the Pliocene epoch.

Earth is heading towards a climate that last existed more than three million years ago (Ma) during the 'mid-Pliocene warm period'1, when atmospheric carbon dioxide concentrations were about 400 parts per million, global sea level oscillated in response to orbital forcing2,3 and peak global-mean sea level (GMSL) may have reached about 20 metres above the present-day value4,5. For sea-level rise of this magnitude, extensive retreat or collapse of the Greenland, West Antarctic and marine-based sectors of the East Antarctic ice sheets is required. Yet the relative amplitude of sea-level variations within glacial-interglacial cycles remains poorly constrained. To address this, we calibrate a theoretical relationship between modern sediment transport by waves and water depth, and then apply the technique to grain size in a continuous 800-metre-thick Pliocene sequence of shallow-marine sediments from Whanganui Basin, New Zealand. Water-depth variations obtained in this way, after corrections for tectonic subsidence, yield cyclic relative sea-level (RSL) variations. Here we show that sea level varied on average by 13 ± 5 metres over glacial-interglacial cycles during the middle-to-late Pliocene (about 3.3-2.5 Ma). The resulting record is independent of the global ice volume proxy3 (as derived from the deep-ocean oxygen isotope record) and sea-level cycles are in phase with 20-thousand-year (kyr) periodic changes in insolation over Antarctica, paced by eccentricity-modulated orbital precession6 between 3.3 and 2.7 Ma. Thereafter, sea-level fluctuations are paced by the 41-kyr period of cycles in Earth's axial tilt as ice sheets stabilize on Antarctica and intensify in the Northern Hemisphere3,6. Strictly, we provide the amplitude of RSL change, rather than absolute GMSL change. However, simulations of RSL change based on glacio-isostatic adjustment show that our record approximates eustatic sea level, defined here as GMSL unregistered to the centre of the Earth. Nonetheless, under conservative assumptions, our estimates limit maximum Pliocene sea-level rise to less than 25 metres and provide new constraints on polar ice-volume variability under the climate conditions predicted for this century.

The volcano mouse Neotomodon alstoni of central Mexico, a biological model in the study of breeding, obesity and circadian rhythms.

The "Mexican volcano mouse" Neotomodon alstoni, is endemic of the Transverse Neovolcanic Ridge in central Mexico. It is considered as least concern species and has been studied as a potential laboratory model from different perspectives. Two lines of research in neuroendocrinology have been addressed: reproduction and parental care, particularly focused on paternal attention and the influence of testosterone, and studies on physiology and behavior of circadian rhythms, focused on the circadian biology of the species, its circadian locomotor activity and daily neuroendocrine regulation of metabolic parameters related to energy balance. Some mice, when captive, spontaneously develop obesity, which allows for comparisons between lean and obese mice of daily changes in neuronal and metabolic parameters associated with changes in food intake and locomotor activity. This review includes studies that consider this species an attractive animal model where the alteration of circadian rhythms influences the pathogenesis of obesity, specifically with the basic regulation of food intake and metabolism and differences related to sex. This study can be considered as a reference to the comparative animal physiology among rodents.

Effect of the earthquake-tsunami (Chile, 2010) on toxic metal content in the Chilean abalone mollusc Concholepas concholepas.

Toxic metal content were measured in samples of mollusc Concholepas concholepas obtained from the Chilean coast. Samples were collected during two periods, one before and one after the earthquake-tsunami which occurred in the Maule Region, Chile, February 27th, 2010 as a result of an earthquake with a magnitude of 8.8. Quantification of toxic metals in samples of hepatopancreas and muscle tissue was performed using flame atomic absorption spectroscopy. The analytical methodology was validated with certified reference material. The content means measured in muscle tissue for January 2010 were Cu: 10.3; Cr: 0.7; Cd: < 0.1; Mn: 3.6 and Zn: 38.6 µg g-1 (dry weight). For October 2014, the means were Cu: 8; Cr: 2.4; Cd: < 0.1; Mn: 5.6 and Zn: 45.4 µg g-1 (dry weight). In hepatopancreas tissue, the content means were Cu: 14.8; Cr: 2.4; Cd: 246.2; Mn: 4.4 and Zn: 1552.9 µg g-1 (dry weight). For October 2014, the means were Cu: 53.7; Cr: 3.5; Cd: 118; Mn: 13.4 and Zn: 1352.3 µg g-1 (dry weight). Cd, Cr, Cu, Mn and Zn content in the samples of hepatopancreas were generally higher than those recorded in muscle tissue however they were not always statistically significant. Statistical analysis showed that Cu and Mn content in the post-tsunami period increased in the hepatopancreas tissue. The concentrations of Cd, Cr, Cu, Mn, and Zn measured in the muscular tissue (edible part) of the species Conchalepas concholepas, were lower than the maximum contents allowed by the current legislation (FAO/WHO, 2004; EU, 2001) and its consumption is not a risk to human health.

Chitosan-triclosan particles modulate inflammatory signaling in gingival fibroblasts.

BACKGROUND AND OBJECTIVES: An important goal of periodontal therapy is the modulation of the inflammatory response. To this end, several pharmacological agents have been evaluated. Triclosan corresponds to an antibacterial and anti-inflammatory agent currently used in periodontal therapy. Chitosan is a natural polymer that may act as a drug delivery agent and exerts antibacterial and anti-inflammatory activities. Therefore, an association between both molecules might be useful to prevent inflammation and tissue destruction in periodontal tissues. MATERIAL AND METHODS: In the present study, we have generated chitosan-triclosan particles and evaluated their morphology, charge, biocompatibility and gene expression analysis in human gingival fibroblasts. RESULTS: The chitosan-triclosan particles size and Z potential were 129 ± 47 nm and 51 ± 17 mV respectively. Human gingival fibroblast viability was not affected by chitosan-triclosan. A total of 1533 genes were upregulated by interleukin (IL)-1ß. On the other hand, 943 were downregulated in fibroblasts stimulated with IL-1ß plus chitosan-triclosan particles. Fifty-one genes were identified as molecular targets upregulated by IL-1 ß and downregulated by the chitosan-triclosan particles. The gene ontology analysis revealed that these genes were enriched in categories related to biological processes, molecular function and cellular components. Furthermore, using real-time reverse transcription-polymerase chain reaction beta-actin, fibronectin, interleukin-6 and IL-1b genes were confirmed as targets upregulated by IL-1ß and downregulated by chitosan-triclosan particles. CONCLUSION: Our results show that chitosan-triclosan particles are able to modulate the inflammatory response in gingival fibroblasts. This effect might be useful in the prevention and/or treatment of inflammation in periodontal diseases.

Resiniferatoxin lowers TNF-α, NO and PGE2 in the intestinal phase and the parasite burden in the muscular phase of Trichinella spiralis infection.

During the course of infection with Trichinella spiralis, an inflammatory response is triggered at the intestinal level in the host, playing a crucial role in the expulsion and elimination of the parasite. However, several studies have demonstrated that this inflammatory response is harmful to the host; hence, the importance of studying molecules with therapeutic potential like resiniferatoxin, which is known to have an anti-inflammatory effect both in vitro and in vivo. In this article, we evaluated the anti-inflammatory activity of resiniferatoxin during the intestinal phase of T. spiralis infection by quantitatively determining the levels of TNF-α, NO and PGE2 as well as the percentage of eosinophils in the blood and intestinal pathology. In addition, parasite burden was determined during the muscle infection. Our results show that resiniferatoxin lowered the serum levels of TNF-α, NO and PGE2 , as well as the percentage of eosinophils in the blood and intestinal pathology during the intestinal infection. Moreover, resiniferatoxin also lowered the parasite burden in muscle, resulting in a reduction of the humoral response (IgG) associated to treatment with resiniferatoxin. These findings suggest a potential therapeutic use of the anti-inflammatory effect of resiniferatoxin, which also contributes to host defence against the challenge of T. spiralis infection.

Resiniferatoxin modulates the Th1 immune response and protects the host during intestinal nematode infection.

In the early stage of the intestinal phase of Trichinella spiralis infection, the host triggers a Th1-type immune response with the aim of eliminating the parasite. However, this response damages the host which favours the survival of the parasite. In the search for novel pharmacological strategies that inhibit the Th1 immune response and assist the host against T. spiralis infection, a recent study showed that resiniferatoxin had anti-inflammatory activity contributed to the host in T. spiralis infection. In this study, we evaluated whether RTX modulates the host immune response through the inhibition of Th1 cytokines in the intestinal phase. In addition, it was determined whether the treatment with RTX affects the infectivity of T. spiralis-L1 and the development of the T. spiralis life cycle. Our results show that RTX decreased serum levels of IL-12, INF-γ, IL-1ß, TNF-α and parasite burden on muscle tissue. It was observed that T. spiralis-L1 treated with RTX decreased their infectivity affecting the development of the T. spiralis life cycle in mouse. These results demonstrate that RTX is able to inhibit the production of Th1 cytokines, contributing to the defence against T. spiralis, which places it as a potential drug modulator of the immune response.

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.

BACKGROUND: Recently, fibroblast growth factor receptor 1 (FGFR1) was discovered in squamous cell carcinomas (SCC) of the lung with FGFR1 amplification described as a promising predictive marker for anti-FGFR inhibitor treatment. Only few data are available regarding prevalence, prognostic significance and clinico-pathological characteristics of FGFR1-amplified and early-stage non-small cell lung carcinomas (NSCLC). We therefore investigated the FGFR1 gene status in a large number of well-characterised early-stage NSCLC. METHODS: FGFR1 gene status was evaluated using a commercially available fluorescent in situ hybridisation (FISH) probe on a tissue microarray (TMA). This TMA harbours 329 resected, formalin-fixed and paraffin-embedded, nodal-negative NSCLC with a UICC stage I-II. The FISH results were correlated with clinico-pathological features and overall survival (OS). RESULTS: The prevalence of an FGFR1 amplification was 12.5% (41/329) and was significantly (P<0.0001) higher in squamous cell carcinoma (SCC) (20.7%) than in adenocarcinoma (2.2%) and large cell carcinoma (13%). Multivariate analysis revealed significantly (P=0.0367) worse 5-year OS in patients with an FGFR1-amplified NSCLC. CONCLUSIONS: FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic marker. Its potential role as a predictive marker for targeted therapies or adjuvant treatment needs further investigation.

Chitosan and platelet-derived growth factor synergistically stimulate cell proliferation in gingival fibroblasts.

BACKGROUND AND OBJECTIVE: Chitosan is a naturally derived polymer that may be applied in periodontal therapy for tissue-reconstruction purposes. Previous studies have shown that chitosan may stimulate tissue healing. However, reports exploring the cellular responses stimulated by chitosan are lacking. In the present study we analyzed whether chitosan may promote cell proliferation in primary cultures of human gingival fibroblasts. MATERIAL AND METHODS: Chitosan particles were generated, and their size, zeta potential and morphology were characterized using transmission and scanning electron microscopy and zetasizer analysis. The biocompatibility of chitosan particles was analyzed using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell-viability assay and by detecting the release of lactate dehydrogenase into the cell-culture medium. The total number of cells was estimated by staining with crystal violet followed by measurement of the absorbance at 560 nm on a microplate reader. Cell proliferation was studied by detecting proliferating cell nuclear antigen protein levels, immunofluorescence for Ki67 and incorporation of 5'-bromo-2'-deoxyuridine. RESULTS: The sizes of the chitosan particles generated were in the micrometer and nanometer ranges. Cell viability was increased in the presence of chitosan. Moreover, the combination of chitosan and platelet-derived growth factor (PDGF-BB) potently stimulated cell viability, cell proliferation and activation of the ERK1/2 pathway involved in cell proliferation. CONCLUSIONS: The present study shows that chitosan is well tolerated by gingival fibroblasts and is able to stimulate cell proliferation through the ERK1/2 signaling pathway. A synergistic response between chitosan and growth factors (such as PDGF-BB) may stimulate cell proliferation in gingival fibroblasts exposed to this biomaterial.

Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study.

BACKGROUND: In older patients, comorbidities competed with cancer for mortality risk. We assessed the prognostic value of comorbidities in older patients with cancer. PATIENTS AND METHODS: We analysed all patients >70 years of age with colorectal, breast, prostate, or lung cancer included in the prospective ELCAPA cohort. The Cumulative Illness Rating Scale-Geriatrics (CIRS-G) score was used to assess comorbidities. The primary endpoint was overall survival (OS) at 3, 12, and 36 months. The adjusted difference in the restricted mean survival time (RMST) was used to assess the strength of the relationship between comorbidities and survival. RESULTS: Of the 1551 patients included (median age 82 years; interquartile range 78-86 years), 502 (32%), 575 (38%), 283 (18%), and 191 (12%) had colorectal, breast, prostate, and lung cancer, respectively, and 50% had metastatic disease. Hypertension, kidney failure, and cognitive impairment were the most common comorbidities (67%, 38%, and 29% of the patients, respectively). A CIRS-G score >17, two or more severe comorbidities, more than seven comorbidities, heart failure, and cognitive impairment were independently associated with shorter OS. The greatest effect size was observed for CIRS-G >17 (versus CIRS-G <11): at 36 months, the adjusted differences in the RMST (95% confidence interval) were -6.0 months (-9.3 to -2.6 months) for colorectal cancer, -9.1 months (-13.2 to -4.9 months) for breast cancer, -8.3 months (-12.8 to -3.9 months) for prostate cancer, and -5.5 months (-9.9 to -1.1 months) for lung cancer (P < 0.05 for all). CONCLUSIONS: Comorbidities' type, number, and severity were independently associated with shorter OS. A 17-point cut-off over 56 for the total CIRS-G score could be considered in clinical practice.

[Assessment of proliferation: core biopsy or resection specimen? Discrepancies in breast cancer with low and high proliferation]. / Bestimmung der Proliferation: Stanze oder Resektat?: Diskrepanzen bei niedrig und stark proliferierenden Mammakarzinomen.

BACKGROUND: The assessment of the proliferation fraction is becoming more and more important; however, there is no consensus concerning optimal validation. Depending on the institute the proliferation fraction is determined either from a core biopsy (SB) or resection specimen (OP). PATIENTS AND METHODS: The interobserver variability and the results of SB and OP were investigated whereby two pathologists independently estimated the proliferation fraction of 90 cases of invasive breast cancer. The results (Ki-67) were quantified, categorized, and compared. RESULTS: Identical (accuracy of 5% steps) results between the 2 pathologists were achieved in 43% (n=39) for SB, 47% (n=42) for OP and 60% (n=54) for SB versus OP. When categorizing the proliferation fraction (low ≤ 15%, moderate 20-30% and high ≥ 35%) the following results were achieved: 76% (n=68) for SB, 82% (n=74) for OP and 81% (n=73) for SB versus OP. CONCLUSIONS: There was a clear interobserver variability (SB: kappa=0.32, OP: kappa=0.34) but this could be dramatically improved by forming proliferation categories (SB: kappa=0.62, OP: kappa=0.72, 60 versus 81%). In SB with a low proliferation fraction a repeated analysis in OPs can be advisable as a higher proliferation fraction is observed in up to 12% of OPs.

[In vitro andulafungin susceptibility of 100 of Candida strains obtained previously to the introduction of this echinocandin in Chile]. / Susceptibilidad in vitro a anidulafungina en 100 cepas de especies de Candida aisladas previo a la introducción de esta equinocandina en Chile.

Fungi, particularly yeasts, have become important opportunistic pathogens that can be resistant to antifungal agents or develop resistance. To address this problem, new molecules such as echinocandins, have been developed. Susceptibility to anidulafungin was studied in yeasts isolated previous to the introduction of this drug in Chile. One hundred strains of different yeast species isolated from invasive fungal infections during 2007 and 2008 were studied. Susceptibility testing of anidulafungin was performed by broth microdilution according to CLSI. All strains were susceptible to anidulafungin. MIC50 and MIC90 were 0.125 µg/mL and 1 µg/mL, respectively. Compared to other yeasts, C. parapsilosis showed a slight increase in the MICs for anidulafungin (MIC50, 1 µg/mL, MIC90, 2 µg/mL), but remained within the susceptible range. Both, fluconazole resistant (8) and dose dependent susceptible strains (16) were susceptible to anidulafungin. In vitro, this echinocandin appears to be an effective therapeutic alternative.

[EGFR mutation analysis in non-small-cell lung cancer : Experience from routine diagnostics]. / EGFR-Mutationsanalyse beim nichtkleinzelligen Lungenkarzinom : Erfahrungen aus der Routinediagnostik.

BACKGROUND: Some patients with non-small cell lung cancer (NSCLC) respond well to therapy with tyrosine kinase inhibitors (TKI). Somatic mutation of the epidermal growth factor receptor (EGFR) gene is an important predictive marker for TKI response. PATIENTS AND METHODS: We performed EGFR mutation analysis in 307 NSCLC (exon 18-21). The data were analyzed for associations with clinical-pathological parameters. RESULTS: Relevant EGFR mutations were found in 25/307 NSCLC (8.1%; 178 biopsies and 129 cytologies). Most mutations were found in exon 19 (50%) followed by the L858R point mutation in exon 21 (12.5%). EGFR mutations were significantly more common in women than in men (16.8% vs. 2.7%; p<0.001) and in adenocarcinoma than in other carcinoma subtypes (11.4% vs. 3.8%; p=0.017). EGFR mutation was associated with TTF-1 positivity (p<0.041). Almost all (96%) mutated NSCLC were TTF-1 positive. CONCLUSION: In Central Europe, the prevalence of relevant EGFR mutations in NSCLC is <10% of patients with NSCLC. EGFR mutations are more common in women and TTF-1 positive adenocarcinomas. Mutation analysis can be performed both from biopsies and cytologies.

Conformational and physicochemical properties of quinoa proteins affected by different conditions of high-intensity ultrasound treatments.

Quinoa proteins (QP) have promise as a potential source of novel food ingredients, and it is of great interest to know how high-intensity ultrasound (HIUS) treatments affect the properties of QP. This work aimed to study the impact of on-off time-pulses of HIUS treatments on the structural and physicochemical properties of QP; samples were treated at 5, 10, 20, and 30 min with on-off pulses of 10 s/10 s, 5 s/1 s, and 1 s/5 s). Structural changes were evaluated using PAGE-SDS, circular dichroism, fluorescence spectroscopy, and differential scanning calorimetry. Meanwhile, physicochemical properties were also examined, including solubility, Z-average, polydispersity index PDI, and Z-potential. PAGE-SDS showed the appearance of polypeptides over 190 kDa in HIUS samples-treated. All samples presented 15.6% α-helices, 31.3% ß-sheets, 21.8% ß-rotations, and 31.4% random coils independent of the HIUS treatment. ß-Turn structures and "random coils" were not affected by HIUS. When US 10 s/10 s and 1 s/5 s were applied, an increase in the % α-helix and a decrease in ß-fold were observed, which could indicate a small conversion of ß-folds to α-helices. Fluorescence spectra for all HIUS showed a significant increase (23%) of average fluorescence intensity and a decrease of λmax in relation to that of the control (346 dnm and 340 nm average HIUS treatment). DSC showed one endotherm in all cases (81.6-99.8 °C), and an increase in Td was observed due to the effect of the HIUS treatment. HIUS caused a 48% increase in solubility. The Z-average of the HIUS samples compared to that of the controls showed an increase from 37.8 to 47.3 nm. PDI and Z-potential values from the QP controls and the HIUS samples did not show significance differences and presented average values of 0.466 ±â€¯0.021 (PDI) and -16.63 ±â€¯0.89 (Z-potential). It is possible to conclude that HIUS treatments affect the secondary and tertiary structure of quinoa proteins, and these changes resulted in an increase of solubility and particle size. HIUS treatment as a new and promising technology that can improve the QP solubility properties and in that way allow its use as an ingredient with a good source of protein to develop different types of beverages/protein sauces.

Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.

BACKGROUND: Gefitinib is active in patients with pretreated non-small-cell lung cancer (NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced NSCLC followed by chemotherapy at disease progression. PATIENTS AND METHODS: In all, 63 patients with chemotherapy-naive stage IIIB/IV NSCLC received gefitinib 250 mg/day. At disease progression, gefitinib was replaced by cisplatin 80 mg/m(2) on day 1 and gemcitabine 1250 mg/m(2) on days 1, 8 for up to six 3-week cycles. Primary end point was the disease stabilization rate (DSR) after 12 weeks of gefitinib. RESULTS: After 12 weeks of gefitinib, the DSR was 24% and the response rate (RR) was 8%. Median time to progression (TtP) was 2.5 months and median overall survival (OS) 11.5 months. Never smokers (n = 9) had a DSR of 56% and a median OS of 20.2 months; patients with epidermal growth factor receptor (EGFR) mutation (n = 4) had a DSR of 75% and the median OS was not reached after the follow-up of 21.6 months. In all, 41 patients received chemotherapy with an overall RR of 34%, DSR of 71% and median TtP of 6.7 months. CONCLUSIONS: First-line gefitinib monotherapy led to a DSR of 24% at 12 weeks in an unselected patients population. Never smokers and patients with EGFR mutations tend to have a better outcome; hence, further trials in selected patients are warranted.

Immunophenotypic profile of tumor buds in breast cancer.

BACKGROUND: Tumor buds are associated with lympho-vascular invasion and lymph node metastases leading to the assumption that they are involved in the early metastatic process. Hence, it would be important to know if tumor buds can be targeted with the most widely used targeted therapies in breast cancer (BC) and if changes in hormone and Her2 status occur. The aim of this study was to answer these questions by determining whether hormone receptor (HR) and Her2 status are expressed in the tumor buds of a large cohort of BCs. DESIGN: We constructed a tumor bud next-generation tissue microarray (ngTMA) consisting of n = 199 BCs of non-special type. Generally, two 1 mm punches were taken from the tumor bud areas in the periphery (PTB) and within the tumor center (ITB). HR and Her2 status was assessed using immunohistochemistry and fluorescence in situ hybridization, respectively. HR status was positive if ≥1% of tumor bud cells were positive. Her2 status was considered positive if bud cells showed strong complete membranous Her2 over-expression or Her2 amplification. RESULTS: Most tumor buds were positive for estrogen (ER) (PTB: 86%; ITB: 88.3) and progesterone receptor (PgR) (PTB: 72%; ITB: 72.8%) and Her2 was positive in: PTB 11.5% and ITB 11%. A difference between the main tumor mass and tumor buds (PTB and ITB) was seen for PgR in 3.5% of cases (n = 7). No differences were seen for ER and Her2 between tumor buds and main tumor mass. CONCLUSION: Most tumor buds (96.5%) share the same HR and Her2 expression profile of the main tumor mass, implying that tumor buds relay on the same pathways as the main tumor mass and might be equally responsive to targeted therapies.

Reconstrucción mandibular con cortical autóloga auto trasplantada del sitio quirúrgico en queratoquiste, revisión de literatura y reporte de caso / Mandibular reconstruction with autologous cortical bone transplanted from the surgical site in keratocyst, literature review, and case report

El queratoquiste es un quiste odontogénico en el cual se describen diferentes opciones terapéuticas tanto conservadores como agresivas, con diferentes tasas de éxito y recidivas. Dependiendo del tratamiento, las técnicas más agresivas presentan mejores resultados, pero involucran un mayor defecto óseo en la zona tratada versus las técnicas conservadoras. El propósito de este reporte de caso es documentar una técnica quirúrgica utilizada en un paciente masculino de 17 años que, tras un tratamiento descompresivo de 8 meses, fue sometido a cirugía con enucleación de la lesión remanente más curetaje mecánico perilesional y uso de solución de Carnoy no modificada, preservando la cortical ósea vestibular mandibular tratada con solución de Carnoy no modificada y reposicionando este segmento óseo mediante osteosíntesis. Se realizó seguimiento clínico e imagenológico postoperatorio de 1 año verificando la remisión del quiste y la neoformación ósea en la zona intervenida. El uso de esta alternativa terapéutica permite evitar el colapso de los tejidos blandos en el defecto óseo subyacente y aportar tejido óseo autógeno tratado que permite una funcionalidad de tramado óseo al cual pueden migrar los elementos celulares para aportar en la regeneración tisular local.

The keratocyst is an odontogenic cyst in which different conservative and aggressive therapeutic options are described, with different success rates and recurrences. Depending on the treatment, the most aggressive techniques present better results but involve a more significant bone defect in the treated area compared to conservative techniques. The purpose of this case report is to document a surgical technique used in a 17-year-old male patient who underwent surgery after eight months of decompressive treatment with enucleation of the remaining lesion plus perilesional mechanical curettage and use of Carnoy's solution unmodified, preserving the mandibular vestibular bone cortex treated with unmodified Carnoy's solution and repositioning this bone segment by osteosynthesis. A one-year postoperative clinical and imaging follow-up was carried out, verifying the remission of the cyst and the new bone formation in the operated area. This therapeutic alternative makes possible to avoid the collapse of the soft tissues in the underlying bone defect and provide treated autogenous bone tissue that allows a bone mesh functionality to which the cellular elements can migrate to contribute to local tissue regeneration.

Uso de Sistema Vivostat® como hemoderivado sellador de abordajes en cirugía ortognática y reconstrucciones de los maxilares, reporte de 23 casos / Use of the Vivostat® system as a sealing blood product for approaches in orthognathic surgery and maxillary reconstructions, report of 23 cases

El presente trabajo tiene como propósito presentar 23 casos operados en distintas prácticas privadas, donde se utilizaron adhesivos de fibrina para: cirugía ortognática bimaxilar, expansión palatina rápida asistida quirúrgicamente (SARPE), y reconstrucciones de rebordes atróficos maxilares y mandibulares empleando injertos e implantes. El uso del adhesivo de fibrina del sistema Vivostat® permitió no solo sellar los abordajes quirúrgicos, sino también fue un excelente complemento en estas cirugías para la cobertura de la mucosa de fosas nasales y mucosa antral que se dañan durante las osteotomías y accesos quirúrgicos. Junto con adquirir ventajas, como variabilidad de factores de crecimiento y protección de los injertos subyacentes en las regiones operadas, se obtienen asimismo una posible disminución de la incidencia en los sangramientos postoperatorios, principalmente epistaxis; con lo cual se brinda al paciente una mejor recuperación en el postoperatorio y evita la posibilidad de dehiscencias y, o aperturas de heridas operatorias con exposición de injertos y de elementos de osteosíntesis subyacentes.

The purpose of this paper is to present 23 operative cases in different private practices, where fibrin adhesives were used for: bimaxillary orthognathic surgery, surgically assisted rapid palatal expansion (SARPE), and maxillary and mandibular atrophic ridge reconstructions using grafts and implants. The use of the fibrin adhesive of the Vivostat® system allowed not only sealing the surgical approaches, but was also an excellent complement in these surgeries for covering the mucosa of the nasal passages and antral mucosa that are damaged during osteotomies and surgical accesses. Along with acquiring advantages, as well as growth factors and protection of the underlying grafts in the operated regions, a possible decrease in the incidence of postoperative bleeding was obtained, mainly epistaxis; with which the patient is given a better recovery in the postoperative period and avoids the possibility of dehiscences and/or openings of surgical wounds with exposure of grafts and underlying osteosynthesis elements.

Vigilancia activa en carcinoma papilar tiroideo de bajo riesgo (parte I): concepto, epidemiología y situación actual en el mundo

Resumen En las últimas décadas, la creciente identificación de nódulos tiroideos ha dado lugar a un incremento dramático en el diagnóstico y tasa de incidencia del cáncer de tiroides, sin embargo, su mortalidad se ha mantenido estable. La mayor fracción de este incremento es atribuible al creciente uso de tecnologías de diagnóstico, que ha identificado un número cada vez mayor de cánceres papilares de tiroides (CPT), en su gran mayoría pequeños y de bajo riesgo clínico. La mayoría de estos tumores no generarán morbilidad o mortalidad a pesar de no ser tratados. La práctica clínica ha evolucionado hacia un tratamiento menos agresivo de los CPTs. La vigilancia activa (VA) ha surgido como una nueva alternativa terapéutica dentro del algoritmo de tratamiento, que tiene como objetivo reconocer a un potencial grupo minoritario de pacientes en quienes sus carcinomas papilares tiroideos sí progresarán clínicamente y, por lo tanto, en ellos un tratamiento quirúrgico resulte en mayor beneficio que perjuicio. En esta revisión nos planteamos como objetivo describir la epidemiología del carcinoma papilar tiroideo, el concepto de vigilancia activa en esta área y los resultados clínicos obtenidos mediante este abordaje terapéutico en las distintas experiencias realizadas en el mundo hasta la fecha.

Abstract In recent decades, the increasing identification of thyroid nodules has led to a dramatic increase in the diagnosis and incidence rate of thyroid cancer. However, their mortality has remained stable. The largest fraction of this increase is attributable to the growing use of diagnostic technologies, which has identified an increasing number of mostly small, low clinical risk papillary thyroid cancers (PTC). Most of these tumors will not generate morbidity or mortality despite being untreated. Clinical practice has evolved towards a less aggressive treatment of PTC's. Active surveillance (AS) has emerged as a new therapeutic alternative within the treatment algorithm, which aims to recognize a potential minority group of patients in whom their thyroid papillary carcinoma will progress clinically, and therefore in whom surgical treatment will result in greater benefit than harm. In this review we aim to describe the epidemiology of papillary thyroid carcinoma, the concept of active surveillance in this area and the clinical results obtained by this therapeutic approach in the different experiences carried out in the world until now.

Vigilancia activa en carcinoma papilar tiroideo de bajo riesgo (parte II): historia de progresión de la enfermedad, calidad de vida y costo-efectividad

Resumen El aumento dramático en la incidencia del cáncer de tiroides de las últimas décadas, el cual se debe principalmente a la mayor detección de microcarcinomas papilares de tiroides (MCPT), ha generado un aumento considerable de los costos asociados a la atención del cáncer de tiroides. A pesar de este aumento de la incidencia a nivel mundial, la mortalidad asociada a estos tumores se ha mantenido sin cambios significativos. En consecuencia, varios grupos de investigadores han sugerido que se ha producido un sobrediagnóstico y un sobretratamiento de los carcinomas papilares de tiroides (CPT) de bajo riesgo. La vigilancia activa (VA) ha surgido como una nueva alternativa terapéutica para estos tumores, con excelentes resultados oncológicos, menores tasas de complicaciones y que podría ayudar a reducir los costos económicos. No obstante, a pesar de los alentadores resultados de la VA, su implementación en la práctica depende de muchos aspectos entre los cuales se encuentran las características radiológicas del tumor, las características clínicas del paciente, factores psicosociales y socioeconómicos. En esta revisión nos enfocaremos en describir la evidencia acumulada hasta la fecha respecto de la historia natural de la cinética del CPT, costo-efectividad de VA, y las limitaciones actuales para su implementación.

Abstract The dramatic increase in the incidence of thyroid cancer in recent decades, which is primarily due to increased detection of papillary thyroid microcarcinomas (PTCM), has led to a significant increase in the costs associated with thyroid cancer care. Despite this increase in the worldwide incidence, the mortality associated with these tumors has remained unchanged. Consequently, several groups of researchers have suggested that low-risk papillary thyroid carcinomas (PTC) have been overdiagnosed and overtreated. Active surveillance (AS) has emerged as a new therapeutic alternative for these tumors, with excellent oncological results, lower complication rates, and which could help reduce economic costs. However, despite the encouraging results of AS, its implementation in practice depends on many aspects including the radiological characteristics of the tumor, the clinical characteristics of the patient, psychosocial factors and socioeconomic factors. In this review we will focus on describing the evidence accumulated to date regarding the natural history of PTC kinetics, cost effectiveness of VA, and current limitations to its implementation.

Evaluación de fuerza de concordancia de hallazgos de endometriosis en RM y laparoscopía: análisis de una serie de casos / Assessment concordance of endometriosis findings on MRI and laparoscopy: analysis of a series of cases

OBJETIVO: Evaluar concordancia de sitios de hallazgos de endometriosis profunda encontrados por RM y laparoscopia. MATERIALES Y MÉTODOS: Estudio retrospectivo, no experimental, concordancia intertécnica. Se recolectaron datos en nuestra institución de todos los informes de RM de pelvis que incluyeran la palabra "endometriosis", entre mayo de 2015 y abril de 2018 (36 meses), identificando 339 registros. Se establecieron criterios de inclusión. De los 339 registros, 62 pacientes fueron excluidas por cirugía antes de la RM. Otras 243 pacientes fueron excluidas porque no presentaban registro de protocolo quirúrgico posterior a la RM. 34 pacientes cumplieron los criterios de inclusión del estudio, lo que equivale al 10% de las RM estudiadas. Se revisaron las ubicaciones de los implantes endometriósicos informados en RM y se correlacionaron con los hallazgos encontrados en la cirugía. Se confecciono tabla para identificar la presencia/ausencia de implantes en las ubicaciones descritas en la literatura. Análisis estadístico mediante software Stata, aplicando kappa ponderada con intervalo de confianza de 95%. RESULTADOS: El promedio de edad de las pacientes llevadas a cirugía fue de 38 años. Los lugares con correlación moderada-importante (0.41-0.80) correspondieron a útero, recto-sigmoides, ovario, vagina y fondos de saco. CONCLUSIÓN: La RM de Pelvis es fundamental en la evaluación de pacientes con endometriosis en las que se plantea un manejo quirúrgico, con el objetivo de caracterizar la ubicación, forma y número de lesiones, y así lograr un satisfactorio tratamiento laparoscópico.

OBJECTIVE: To assess inter-observer reliability of sites of deep endometriosis findings found by MRI and laparoscopy. MATERIALS AND METHODS: Retrospective, non-experimental study, inter-observer reliability. Data were collected at our institution from all pelvic MRI reports that included the word "endometriosis", between May 2015 and April 2018 (36 months), identifying 339 records. The following were established as inclusion criteria. Of the 339 records, 62 patients were excluded for surgery prior to MRI. Another 243 patients were excluded because they had no record of the surgical protocol after the MRI. 34 patients met the study inclusion criteria, equivalent to 10% of the MRIs studied. The locations of the endometrial implants reported on MRI were reviewed and correlated with the findings found in the surgery. A table was prepared to identify the presence / absence of implants in the locations described in the literature. Statistical analysis using Stata software, applying weighted kappa with a 95% confidence interval. RESULTS: The average age of the patients undergoing surgery was 38 years. The places with a moderate-important correlation (0.41-0.80) corresponded to the uterus, recto-sigmoid, ovary, vagina, and recto-uterine pouch. CONCLUSION: Pelvic MRI is essential in the evaluation of patients with endometriosis in whom surgical management is proposed, in order to characterize the location, shape and number of lesions, and thus achieve satisfactory laparoscopic treatment.